As a practicing surgical physician associate, I support the removal of the physicians name from controlled substance prescriptions. Many EMRs lack this capability and since it is required to transmit those ordered electronically this inherently causes some level of non compliance. Also, I question the utility as many PAs work at a different site from their physician. We have prescriptive authority to order the medications, what purpose does their name serve? We have our DEA on the prescription already. Please consider removing this antiquated process. 

This change would be immensely helpful. I have received calls from pharmacists from Walmart and CVS stating they need additional physician information in order to fill the prescription I wrote. The prescription includes the physician’s name and NPI, but the computer program does not generate the DEA. While that is not required by law, and my prescription is otherwise compliant with current law, they will not proceed until they have the DEA. Removing the physician name requirement all together will help eliminate confusion and improve patient experience, not to mention reduce delays and additional time burden on the prescribing PA. 

As the Interim Program Director of the Shenandoah University Physician Assistant (PA) Program, I strongly support the petition to remove the requirement that a patient care team physician’s name be included on prescriptions for Schedule II-V medications.

This change is a necessary step in recognizing the autonomous prescribing authority of PAs within the collaborative practice framework. PAs are rigorously trained medical professionals who provide high-quality patient care, and their ability to prescribe controlled substances is already regulated through state licensure, DEA registration, and collaborative practice agreements. Requiring a supervising physician’s name on prescriptions does not enhance patient safety but rather creates administrative burdens that can delay care, contribute to confusion at the pharmacy, and misrepresent the prescribing provider’s role in the patient’s treatment plan.

Removing this requirement aligns with best practices in other states and supports a more efficient and transparent healthcare system. I urge the Board of Medicine to approve this petition and modernize regulations to better reflect the evolving role of PAs in Virginia’s healthcare workforce.

Sincerely,

Erika Francis, DMS, PA-C

Interim Program Director

Shenandoah University PA Program

As a licensed Physician Assistant in Virginia with an independent DEA registration, the removal of the requirement for including the supervising physician's or podiatrist's name on prescriptions for Schedule II-V controlled substances is a necessary and logical step. This adjustment reflects the professional accountability of PAs, as listing a physician's name does improve patient care but instead creates unnecessary administrative burdens. 

Requiring a physician or podiatrists' name on scripts for controlled substances has caused patients to experience delays in having their pain medications filled. PAs hold their own DEA licenses, have completed the required pharmacology training, and have access to the Prescription Monitoring Program. Removing this requirement only increases access to care. 

As the Director of the PA Program at James Madison University, I strongly support the removal of the current requirement that a patient care team physician’s name be included on prescriptions for Schedule II-V medications.  PAs already have prescriptive authority at the state level via licensure, are registered with the DEA federally, and have a practice agreement locally.  Requiring a physician name on a script serves no meaningful purpose.  On the contrary, the rule in fact delays patient care when pharmacists are made to contact PA prescribers when the physician’s name is missing, mostly due to incapable EMR systems.  At best, this rule creates some level of unintentional non-compliance.  And at worst, it is completely illogical and administratively burdensome.

Sincerely,

Jerry Weniger, PhD, PA-C

Director, PA Program

James Madison University

Most PAs have been there, we are in clinic seeing patients when we get the call. The pharmacy needs you to resend the prescription with the collaborating physician's name on it.  We must stop everything and either call the pharmacy or resend the prescription. This takes away from patient care and adds ONE MORE additional bureaucracy to our day. ONE MORE rule that does not make any sense or add benefit to patients. This rule wastes pharmacy's time and takes away from PA's time we could/should be spending with patients.  It adds to burn out with PAs, clinic staff and pharmacy staff. Please tell me how this is value-added to the patient? Often times my prescription will make it onto the PMP in Virginia for my collaborating physician. The MD/DO doesn't even know the patient, and now MY PATIENTS' controlled meds are falsely elevating the MDs' list of prescribed controlled meds. This is a liability. Perhaps this is another reason it can be hard to find collaborators in psychiatry; add that to the critical shortages of psychiatrists. Please help us rid these antiquated rules that hinder patient care and steal valuable time from providers.

Please remove this antiquated rule.  All it does is hinder patient care and unnecessarily increase workload.  

I fully support the removal of physician name on schedule II-V drug prescriptions written by Virginia PAs. As highly trained medical professionals, PAs possess the expertise to safely and effectively prescribe these medications within their scope of practice.

Eliminating this requirement will:

1. Enhance Efficiency and Patient Care 2. Expand Access to Care: PAs are essential healthcare providers, particularly in rural and underserved areas. This regulatory change will empower PAs to provide comprehensive care where physician shortages are present.
3. Reduce Administrative Burden: Removing this requirement will alleviate administrative workload, including pharmacy calls, allowing healthcare teams to focus more on patient care. 4. Reduce unnecessary emergency room visits. 

As a practicing PA and a PA Medicine program director, I strongly support the petition to remove the requirement that a patient care team physician’s name be included on prescriptions for Schedule II-V medications in Virginia.

This outdated requirement places an unnecessary administrative burden on PAs and their collaborating physicians without providing any added benefit to patient safety or care quality. PAs are highly trained, licensed medical professionals who prescribe these medications within their scope of practice and in accordance with state and federal regulations. The current rule creates inefficiencies that can delay patient access to necessary medications and adds redundant documentation requirements that do not enhance oversight or accountability.

Furthermore, this requirement does not align with the prescribing practices in many other states where PAs can prescribe independently within the bounds of their scope of practice. Removing this requirement would modernize Virginia’s approach, reducing administrative barriers and improving workflow efficiency while maintaining high standards of patient care.

I urge the regulatory board to support this petition and remove this requirement, ensuring that PAs can continue to provide timely, effective, and patient-centered care without unnecessary administrative constraints.

I support removing this barrier to patient care

As the healthcare field & scopes of practice change, it is important that legislation change with it in order to support patient-centered, accessible care.